[ TRANSACTION RECORD ]

Roche Holding AG Investment in Telavant — 2023

VERIFIED VECTOR ID: 001534 · tx-062
M SOURCE NODE — FUNDER
Roche Holding AG
Healthcare Switzerland
$7,100,000,000
EQUITY
23/10/2023
Q DESTINATION NODE — RECIPIENT
Telavant
Company United States
Amount (USD)
$7.1B
Flow Type
EQUITY
Transaction Date
23/10/2023
Primary Source
View Filing ↗
Funder Profile [ M ]
Entity Roche Holding AG
AUM 255000
HQ Location Switzerland
Sector Healthcare
Recipient Profile [ Q ]
Entity Telavant
Entity Type Company
Jurisdiction United States
Intelligence Note

Roche Holding AG entered into a definitive agreement to acquire Telavant for 7.1 billion dollars to gain access to a promising therapy for inflammatory bowel disease. The transaction includes the development and commercialization rights in the U.S. and Japan. This deal underscores Roche’s commitment to expanding its immunology portfolio through strategic biotech acquisitions.

Σ
Primary Forensic Source https://www.roche.com/media/releases/med-cor-2023-10-23/
✓ SOURCE LINKED